Vanda Pharmaceuticals | VNDA - Selling And Administration Expenses


Vanda Pharmaceuticals reported $39.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Anika Therapeutics USD 12.91M 17.8M Mar/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Insmed USD 212.48M 26.11M Dec/2025
J&J USD 6.75B 831M Dec/2025
Lexicon Pharmaceuticals USD 39.19M 7.13M Jun/2024
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 308M 40M Dec/2025
Novartis USD 3.3B 137M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Veracyte USD 43.31M 8.43M Dec/2025